Kyungdong Pharmaceutical is actively expanding its portfolio and targeting the market through the launch of new diabetes treatment products.
On the 19th, Kyungdong Pharmaceutical announced that it held a new product launch ceremony at its headquarters in Gwacheon, Gyeonggi-do. On this day, the company introduced a total of six new products, including the DPP-4 inhibitor (Dipeptidyl peptidase-4 inhibitor) class diabetes treatments ‘Ritazine Tablet’, ‘Ritame Tablet’, and ‘Ritame Extended-Release Tablet’, which were released on the 9th.
Ritazine Tablet is a single-agent DPP-4 inhibitor for type 2 diabetes treatment containing linagliptin, whose cardiovascular safety has been proven. It can be taken by patients with chronic kidney disease and other renal impairments without dose adjustment or separate monitoring.
Ritame Tablet and Ritame Extended-Release Tablet are linagliptin-metformin combination products, classified as immediate-release and extended-release formulations, respectively. These products improve convenience for patients who have difficulty controlling blood sugar with metformin monotherapy, the first-line treatment for diabetes. In particular, considering the characteristics of diabetic patients with a high incidence of complications, they were released in various dosages.
Kyungdong Pharmaceutical is strengthening its product lineup to target the growing diabetes treatment market due to an increase in patients. In April, it introduced ‘Pictazine Tablet’, a combination diabetes treatment of sodium-glucose co-transporter (SGLT)-2 and thiazolidinedione (TZD) classes. Along with existing products such as ▲Teneritine ▲Tenerium Extended-Release Tablet ▲Dapazine Tablet ▲Dapamet Extended-Release Tablet ▲Dapamepi Tablet ▲Dapazine SDuo Tablet, the company has built a diverse portfolio of diabetes treatments.
Kim Kyunghoon, CEO of Kyungdong Pharmaceutical, said, “Through the launch of the linagliptin single and combination series, we will provide various treatment options to diabetic patients,” adding, “We will strengthen our position in the chronic disease treatment market, including diabetes, through continuous research and development and new product launches.”
Meanwhile, according to the global market research firm Fortune Business Insights, the global diabetes treatment market size is expected to grow from $79.25 billion (approximately KRW 108.8974 trillion) last year to $153.98 billion (approximately KRW 211.5839 trillion) by 2032. The compound annual growth rate is 7.0%.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
